PK Modeling of L-4-Boronophenylalanine and Development of Bayesian Predictive Platform for L-4-Boronophenylalanine PKs for Boron Neutron Capture Therapy [PDF]
L-4-[(10B)]Boronophenylalanine (BPA) is an amino acid analogue with a boron-10 moiety. It is most widely used as a boron carrier in boron neutron capture therapy.
Woo Hyoung Kim, Hyeong-Seok Lim
exaly +6 more sources
Evaluation of Pharmacokinetics of Boronophenylalanine and Its Uptakes in Gastric Cancer
Boron neutron capture therapy (BNCT), a cellular-level particle radiation therapy, combines boron compounds selectively delivered to tumor tissue with neutron irradiation.
Jiangyan Liu, Liu Jiangyan, Li Yumin
exaly +5 more sources
Boron‐10 carriers and their applications in boron neutron capture therapy [PDF]
Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang +7 more
doaj +3 more sources
Lipoic acid-boronophenylalanine-derived multifunctional vesicles for cancer chemoradiotherapy [PDF]
Cancer remains a major health challenge, with the effectiveness of chemotherapy often limited by its lack of specificity and systemic toxicity. Nanotechnology, particularly in targeted drug delivery, has emerged as a key innovation to address these ...
Liqun Dai +10 more
doaj +4 more sources
Automated radiosynthesis of 2-[18F]BPA for PET-based planning of boron neutron capture therapy (BNCT): rational precursor design, radiofluorination, and characterization of methodology [PDF]
Background Boron neutron capture therapy relies on the selective accumulation of boron-containing compounds in tumor tissue, making accurate quantification of boron distribution essential for effective treatment planning.
Vincenzo Paolillo +4 more
doaj +2 more sources
Boron Neutron Capture Therapy as a Novel Approach for Chondrosarcoma: Case Study of Tumor Reduction and Long-term Control [PDF]
Purpose: Mesenchymal chondrosarcoma (MCS), a rare malignant tumor arising from cartilage-forming tissues, is known for its resistance to conventional therapies.
Junqiang Hong, MD +17 more
doaj +2 more sources
Emerging agents for boron neutron capture therapy: Biomolecular carriers paving the way for precision radiotherapy. [PDF]
Boron neutron capture therapy (BNCT) requires key non‐negotiable technical criteria: megadose administration, precise tumor‐specific targeting, favorable biocompatibility, and sustained tumor retention. Overcoming these interconnected challenges fundamentally depends on biomolecular carriers, which are critical for translating the therapeutic potential
Chen C +6 more
europepmc +2 more sources
Sensitization for proton beam therapy using 10B enriched and natural isotopic abundance of boronophenylalanine [PDF]
Nuclear reactions between proton irradiation and boron via p + 11B→3α (boron proton-capture reaction; BPCR) and n + 10B→α+7Li (boron neutron-capture reaction; BNCR) enhance the cell-killing effects of proton beam irradiation (PBI); however, which ...
Shintaro Shiba +6 more
doaj +2 more sources
Clinical application of boron neutron capture therapy for cancer treatment: A systematic review. [PDF]
This review provides an overview of the development of boron‐containing drugs, and the progress made in clinical studies of BNCT, in order to promote the research and development of accelerator‐based neutron sources, increase the tumor‐targeting of boron drugs, and improve BNCT efficacy to treat malignancies.
Zhou L +7 more
europepmc +2 more sources
Comparison of the Biological Response of a Head and Neck Carcinoma and a Glioblastoma Cell Line Under Neutron Irradiation with BPA Administration [PDF]
Background and objective: In Boron Neutron Capture Therapy, treatment planning is based on a weighted dose in which dose components are weighted with different biological effectiveness (RBE) factors.
Patricia Álvarez-Rodríguez +12 more
doaj +2 more sources

